{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:14:41Z","timestamp":1780082081378,"version":"3.54.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["Grant No. 2021-MS-045"],"award-info":[{"award-number":["Grant No. 2021-MS-045"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"China National Key R&D Project","award":["contract No. 2022YFC2503500"],"award-info":[{"award-number":["contract No. 2022YFC2503500"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Dual antiplatelet therapy (DAPT) is the cornerstone for patients with coronary atherosclerotic heart disease (CHD) undergoing percutaneous coronary intervention (PCI) while increasing the risk of bleeding, particularly when combined with gastrointestinal disease (GID). Rivaroxaban 10 mg once daily is widely used in Asia. This study compared the effects of low-dose rivaroxaban (10 mg daily) plus clopidogrel vs. DAPT in CHD patients with GID undergoing PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective, single-center, randomized controlled trial, eligible CHD patients with GID undergoing PCI were randomized (1:1) to either the dual pathway inhibition (DPI) group (rivaroxaban 10 mg plus clopidogrel 75 mg daily) or the DAPT group (aspirin 100 mg plus clopidogrel 75 mg daily). The primary outcome was Bleeding Academic Research Consortium (BARC) type 2\u20135 bleeding. The secondary outcome was major adverse cardiovascular or cerebrovascular events (MACCE), which included cardiac death, nonfatal myocardial infarction, ischemia-driven target vessel revascularization, all-cause death, stent thrombosis, and stroke during the 6-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1042 patients were enrolled and analyzed (DPI, 522; DAPT, 520). Low-dose rivaroxaban (10 mg daily) plus clopidogrel was non-inferior to DAPT in BARC type 2\u20135 bleeding [8 (1.5%) vs. 6 (1.2%), absolute risk difference 0.38%, 95% confidence interval (CI) (\u2212\u20091.02\u20131.78),\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.0001 for non-inferiority]. Abdominal pain was significantly lower in the DPI group (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.009). Other abdominal discomforts, gastrointestinal bleeding, or MACCE were similar.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In CHD patients with GID undergoing PCI, low-dose rivaroxaban (10 mg daily) plus clopidogrel was non-inferior to DAPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Chinese Clinical Trial Registry ChiCTR2100044319. Registered on March 16, 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10557-025-07682-5","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T16:40:02Z","timestamp":1742661602000},"page":"201-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low-Dose Rivaroxaban vs. Aspirin in Addition to Clopidogrel After Percutaneous Coronary Intervention in Coronary Atherosclerotic Heart Disease Patients with Gastrointestinal Disease"],"prefix":"10.1007","volume":"40","author":[{"given":"Yue","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1979-0287","authenticated-orcid":false,"given":"Xiaozeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"2","key":"7682_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J."},{"key":"7682_CR2","unstructured":"Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. Guidelines for the management of non-ST elevation acute coronary syndromes (2024). Article in Chinese. Chin J Cardiol. 2024,52:(06): 615-646."},{"key":"7682_CR3","unstructured":"Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology Interventional Cardiology Working Group of Chinese Society of Cardiology Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians, et al. Dual antiplatelet therapy in patients with coronary artery disease. Chin J Cardiol. 2021,49:(05): 432-454."},{"key":"7682_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1055\/s-0040-1709520","volume":"120","author":"C Dai","year":"2020","unstructured":"Dai C, Chen Z, Fu J, Qian J, Ge J. Cilostazol for Chinese patients with aspirin intolerance after coronary drug-eluting stent implantation. Thromb Haemost. 2020;120:857\u201365.","journal-title":"Thromb Haemost."},{"key":"7682_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.anai.2012.11.013","volume":"110","author":"CH Feng","year":"2013","unstructured":"Feng CH, White AA, Stevenson DD. Characterization of aspirin allergies in patients with coronary artery disease. Ann Allergy Asthma Immunol. 2013;110:92\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"7682_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrgastro.2011.97","volume":"8","author":"C Sostres","year":"2011","unstructured":"Sostres C, Lanas A. Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol. 2011;8(7):385\u201394.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"27","key":"7682_CR7","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1093\/eurheartj\/ehae324","volume":"45","author":"C Patrono","year":"2024","unstructured":"Patrono C. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. Eur Heart J. 2024;45(27):2362\u201376.","journal-title":"Eur Heart J."},{"issue":"5","key":"7682_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/ehjcvp\/pvab059","volume":"8","author":"P Sarajlic","year":"2022","unstructured":"Sarajlic P, Simonsson M, Jernberg T, B\u00e4ck M, Hofmann R. Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2022;8(5):483\u201391.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"23 Pt A","key":"7682_CR9","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","volume":"72","author":"D Capodanno","year":"2018","unstructured":"Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC\/AHA versus ESC Guidelines on dual antiplatelet therapy: JACC Guideline Comparison. J Am Coll Cardiol. 2018;72(23 Pt A):2915\u201331.","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"7682_CR10","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.33963\/KP.a2022.0283","volume":"80","author":"S Carlin","year":"2022","unstructured":"Carlin S, de Vries TAC, Budaj A, Eikelboom J. Dual pathway inhibition for atherosclerotic cardiovascular disease: recent advances. Kardiol Pol. 2022;80(12):1200\u201310.","journal-title":"Kardiol Pol."},{"issue":"9872","key":"7682_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJM Dewilde","year":"2013","unstructured":"Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107\u201315.","journal-title":"Lancet."},{"issue":"25","key":"7682_CR12","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423\u201334.","journal-title":"N Engl J Med."},{"key":"7682_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.116.025783","volume":"135","author":"CM Gibson","year":"2017","unstructured":"Gibson CM, Pinto DS, Chi G, et al. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy. Circulation. 2017;135:323\u201333.","journal-title":"Circulation."},{"issue":"10081","key":"7682_CR14","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","volume":"389","author":"EM Ohman","year":"2017","unstructured":"Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799\u2013808.","journal-title":"Lancet."},{"key":"7682_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/1074248415578172","volume":"20","author":"E Perzborn","year":"2015","unstructured":"Perzborn E, Heitmeier S, Laux V. Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther. 2015;20:554\u201362.","journal-title":"J Cardiovasc Pharmacol Ther."},{"issue":"1","key":"7682_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"53","author":"W Mueck","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1\u201316.","journal-title":"Clin Pharmacokinet."},{"key":"7682_CR17","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.jacc.2016.06.062","volume":"68","author":"YH Chan","year":"2016","unstructured":"Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2016;68:1389\u2013401.","journal-title":"J Am Coll Cardiol."},{"key":"7682_CR18","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.03.006","volume":"23","author":"S Ogawa","year":"2014","unstructured":"Ogawa S, Ikeda T, Kitazono T, et al. Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry. J Stroke Cerebrovasc Dis. 2014;23:2520\u20136.","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"7682_CR19","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1080\/03007995.2017.1374935","volume":"33","author":"S Kohsaka","year":"2017","unstructured":"Kohsaka S, Murata T, Izumi N, Katada J, Wang F, Terayama Y. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Curr Med Res Opin. 2017;33:1955\u201363.","journal-title":"Curr Med Res Opin."},{"key":"7682_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijcard.2018.03.063","volume":"261","author":"HF Lee","year":"2018","unstructured":"Lee HF, Chan YH, Tu HT, et al. The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation. Int J Cardiol. 2018;261:78\u201383.","journal-title":"Int J Cardiol."},{"issue":"5","key":"7682_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jacc.2018.04.084","volume":"72","author":"YC Lin","year":"2018","unstructured":"Lin YC, Chien SC, Hsieh YC, et al. Effectiveness and safety of standard- and low-dose rivaroxaban in Asians with atrial fibrillation. J Am Coll Cardiol. 2018;72(5):477\u201385.","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"7682_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13063-023-07236-w","volume":"24","author":"T Zhou","year":"2023","unstructured":"Zhou T, Gong Y, Li J, Wang Y, Wang X. Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial. Trials. 2023;24(1):209.","journal-title":"Trials."},{"key":"7682_CR23","unstructured":"Study Group of Gastrointestinal Motility, Study Group of Functional Gastrointestinal Disorders, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on the management of functional dyspepsia (2015, Shanghai). Chinese Journal of Digestion. 2016,36(4): 217-229."},{"key":"7682_CR24","unstructured":"Fang H, Fang X, Guo J. Research on the implementation of the randomized process based on SPSS in data analysis course. Journal of Langfang Normal University (Natural Science Edition). 2016;16(04):20-23+27."},{"key":"7682_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.04.012","volume":"328","author":"YY Zheng","year":"2021","unstructured":"Zheng YY, Wu TT, Guo QQ, et al. Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery disease. Atherosclerosis. 2021;328:1\u201310.","journal-title":"Atherosclerosis."},{"key":"7682_CR26","doi-asserted-by":"crossref","unstructured":"Mega JL, Braunwald E, Mohanavelu S, et al. ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29-38.","DOI":"10.1016\/S0140-6736(09)60738-8"},{"issue":"1","key":"7682_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2\u2013TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9\u201319.","journal-title":"N Engl J Med."},{"key":"7682_CR28","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","volume":"119","author":"JH Alexander","year":"2009","unstructured":"Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877\u201385.","journal-title":"Circulation"},{"issue":"8","key":"7682_CR29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, et al. APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699\u2013708.","journal-title":"N Engl J Med."},{"issue":"3","key":"7682_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40256-016-0161-8","volume":"16","author":"EA Alamneh","year":"2016","unstructured":"Alamneh EA, Chalmers L, Bereznicki LR. Suboptimal use of oral anticoagulants in atrial fibrillation: has the introduction of direct oral anticoagulants improved prescribing practices? Am J Cardiovasc Drugs. 2016;16(3):183\u2013200.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"7","key":"7682_CR31","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1185\/03007995.2016.1170672","volume":"32","author":"E Nguyen","year":"2016","unstructured":"Nguyen E, White CM, Patel MR, et al. Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. Curr Med Res Opin. 2016;32(7):1277\u20139.","journal-title":"Curr Med Res Opin."},{"issue":"4","key":"7682_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s11239-020-02114-7","volume":"50","author":"SU Khan","year":"2020","unstructured":"Khan SU, Khan MZ, Asad ZUA, et al. Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020;50(4):913\u201320.","journal-title":"J Thromb Thrombolysis."},{"issue":"2","key":"7682_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00228-021-03226-6","volume":"78","author":"G Mu","year":"2022","unstructured":"Mu G, Zhang H, Liu Z, et al. Standard- vs low-dose rivaroxaban in patients with atrial fibrillation: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78(2):181\u201390.","journal-title":"Eur J Clin Pharmacol."},{"issue":"4","key":"7682_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0040-1718729","volume":"121","author":"HK Kim","year":"2021","unstructured":"Kim HK, Tantry US, Smith SC Jr, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost. 2021;121(4):422\u201332.","journal-title":"Thromb Haemost."},{"issue":"1","key":"7682_CR35","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jjcc.2016.05.003","volume":"69","author":"Y Numasawa","year":"2017","unstructured":"Numasawa Y, Kohsaka S, Ueda I, et al. Incidence and predictors of bleeding complications after percutaneous coronary intervention. J Cardiol. 2017;69(1):272\u20139.","journal-title":"J Cardiol."},{"key":"7682_CR36","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1001\/jama.2015.2323","volume":"313","author":"Y Han","year":"2015","unstructured":"Han Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the bright randomized clinical trial. JAMA. 2015;313:1336\u201346.","journal-title":"JAMA."},{"key":"7682_CR37","unstructured":"Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. 2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction. Article in Chinese. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47(10):766-783."},{"key":"7682_CR38","doi-asserted-by":"crossref","unstructured":"Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Antithrombotic management of atrial fibrillation patients presenting with coronary artery disease: a consensus document of the Chinese society of cardiology. Cardiol Discov. 2021;1(1)15\u201328.","DOI":"10.1097\/CD9.0000000000000020"},{"key":"7682_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.767987","volume":"9","author":"Y Zhai","year":"2022","unstructured":"Zhai Y, Ye X, Hu F, et al. Updated insights on cardiac and vascular risks of proton pump inhibitors: a real-world pharmacovigilance study. Front Cardiovasc Med. 2022;9: 767987.","journal-title":"Front Cardiovasc Med."},{"issue":"4","key":"7682_CR40","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.mayocp.2021.11.037","volume":"97","author":"M Zhou","year":"2022","unstructured":"Zhou M, Zhang J, Liu J, et al. Proton pump inhibitors and in-hospital gastrointestinal bleeding in patients with acute coronary syndrome receiving dual antiplatelet therapy. Mayo Clin Proc. 2022;97(4):682\u201392.","journal-title":"Mayo Clin Proc."},{"issue":"1","key":"7682_CR41","doi-asserted-by":"publisher","first-page":"2364748","DOI":"10.1080\/09537104.2024.2364748","volume":"35","author":"WB Dai","year":"2024","unstructured":"Dai WB, Ren JY, Hu ST, et al. The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention. Platelets. 2024;35(1):2364748.","journal-title":"Platelets."},{"issue":"2","key":"7682_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/FJC.0000000000000770","volume":"75","author":"J Hernandez-Juarez","year":"2020","unstructured":"Hernandez-Juarez J, Espejo-Godinez HG, Mancilla-Padilla R, et al. Effects of rivaroxaban on platelet aggregation. J Cardiovasc Pharmacol. 2020;75(2):180\u20134.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"1","key":"7682_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11239-023-02821-x","volume":"56","author":"PM Mazzone","year":"2023","unstructured":"Mazzone PM, Capodanno D. Low dose rivaroxaban for the management of atherosclerotic cardiovascular disease. J Thromb Thrombolysis. 2023;56(1):91\u2013102.","journal-title":"J Thromb Thrombolysis."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07682-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:58:22Z","timestamp":1770202702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07682-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7682"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07682-5","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"3 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and received approval from the Institutional Ethics Committee of the General Hospital of Northern Theater Command (approval no. Y(2020)068).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"Written informed consent was obtained from all patients for their participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"We declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}